Results 191 to 200 of about 247,670 (219)
Some of the next articles are maybe not open access.
Diffuse large B-cell lymphoma.
Seminars in Radiation Oncology, 2007Diffuse large B-cell lymphoma (DLBCL) is one of the most common subtypes of non-Hodgkin lymphoma. It is a heterogeneous disease, and a distinctive subgroup of patients with different treatment outcome can be identified based on clinical and molecular prognostic factors.
A. Ng
semanticscholar +3 more sources
Critical Reviews in Oncology/Hematology, 2013
Diffuse large B-cell lymphoma (DLBCL) is the most common lymphoid malignancy in adults accounting for 31% of all NHL in Western Countries. Following, morphological, biological and clinical studies have allowed the subdivision of DLBCLs into morphological variants, molecular and immunophenotypic subgroups and distinct disease entities.
MARTELLI, Maurizio +5 more
+6 more sources
Diffuse large B-cell lymphoma (DLBCL) is the most common lymphoid malignancy in adults accounting for 31% of all NHL in Western Countries. Following, morphological, biological and clinical studies have allowed the subdivision of DLBCLs into morphological variants, molecular and immunophenotypic subgroups and distinct disease entities.
MARTELLI, Maurizio +5 more
+6 more sources
The Lancet Oncology, 2021
BACKGROUND Patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who do not respond to or who have progressive disease after salvage therapies have a poor prognosis.
P. Caimi +17 more
semanticscholar +1 more source
BACKGROUND Patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who do not respond to or who have progressive disease after salvage therapies have a poor prognosis.
P. Caimi +17 more
semanticscholar +1 more source
Hematology/Oncology Clinics of North America, 2016
Systemic (or “non-CNS”) diffuse large B-cell lymphoma (DLBCL) is the most common lymphoma accounting for approximately 30–40 % of all new lymphoma diagnoses in HIV-negative patients and 30–80 % in HIV-infected patients. Both plasmablastic lymphoma and primary CNS lymphoma are considered variants of DLBCL, but will be discussed in detail in separate ...
Stefan K. Barta +2 more
+5 more sources
Systemic (or “non-CNS”) diffuse large B-cell lymphoma (DLBCL) is the most common lymphoma accounting for approximately 30–40 % of all new lymphoma diagnoses in HIV-negative patients and 30–80 % in HIV-infected patients. Both plasmablastic lymphoma and primary CNS lymphoma are considered variants of DLBCL, but will be discussed in detail in separate ...
Stefan K. Barta +2 more
+5 more sources
Treatment strategies for patients with diffuse large B-cell lymphoma.
Cancer Treatment Reviews, 2022Diffuse large B-cell lymphoma (DLBCL) is nowadays a curable disease with the frontline treatment R-CHOP, but 30-40% of patients are still unresponsive or relapse thereafter.
S. Poletto +4 more
semanticscholar +1 more source
BRD4 inhibition sensitizes diffuse large B-cell lymphoma cells to ferroptosis.
Blood, 2023Diffuse large B-cell lymphoma (DLBCL), the most common form of non-Hodgkin lymphoma, is characterized by an aggressive clinical course. In approximately one-third of DLBCL patients, first-line multi-agent immunochemotherapy fails to produce a durable ...
A. Schmitt +19 more
semanticscholar +1 more source
NHL (diffuse large B-cell lymphoma).
BMJ clinical evidence, 2016Non-Hodgkin's lymphoma (NHL) is the sixth most common cancer in the UK; 9443 new cases were diagnosed in the UK in 2002, and it caused 4418 UK deaths in 2003. Incidence rates show distinct geographical variation, with age-standardised incidence rates ranging from 17 per 100,000 in northern America to 4 per 100,000 in south-central Asia. NHL occurs more
Fiona, Kyle, Mark, Hill
openaire +3 more sources
Everolimus in Diffuse Large B-Cell Lymphomas
Future Oncology, 2015Satisfactory treatment of relapsed/refractory diffuse large B-cell lymphoma (DLBCL) is not currently available and novel therapies are needed. mTOR is an intracellular kinase that is part of an aberrantly activated pathway in DLBCL. Preclinical studies in DLBCL cell lines demonstrated that everolimus, an oral selective mTOR inhibitor, induces cell ...
Merli, Michele +4 more
openaire +4 more sources
ALK‐positive diffuse large B‐cell lymphoma
Pediatric Blood & Cancer, 2005AbstractAnaplastic lymphoma kinase (ALK) positive diffuse large B‐cell lymphoma (DLBCL) is a rare subtype of non‐Hodgkins lymphoma. Five such cases have been described in children. We present a 9‐year‐old boy, in whom diagnosis of DLBCL has been established in addition to congenital multiple enchondromatosis. Immunohistopathological evaluation of tumor
Halina, Bubała +4 more
openaire +2 more sources